肝细胞再生刺激素治疗重型肝炎318例疗效分析的对照研究

A Double-blind Study of Hepatic Regenerative Stimulus (HRS) on Advanced Viral Hepatitis:Analysis of 318 Cases

采用解放军第８１医院和南京大学制药厂共同研制的国家一类新药──肝细胞再生刺激素（Ｈｅｐａｔｉｃｒｅｇｅｎｅｒａｔｉｖｅｓｔｉｍｕｌｕｓ，ＨＲＳ），简称肝再生素治疗重型肝炎３１８例总有效率（即存活率）达６９．２％（２２０／３１８）明显优于对照组３０．３％（３３／１０９）（Ｐ＜０．００１）。进一步分析表明：无论是双盲随机对照，非盲随机对照和非对照的开放性研究，各组用ＨＲＳ治疗重型病毒性肝炎的存活率均在７０％左右，而对照组仅为３０％左右，提示：ＨＲＳ治疗重型病毒性肝炎有明显的疗效。

The effects of HRS derived from newborn calves on patients with advanced viral hepatitis (AVH) were observed.The results showed that the total survival rate were 69.2% (220/318) in the HRS treatment group and 30.3% (33/109) in the control group.Among the 318 cases of patients with AVH,the survival rates were 69.9% in 73 cases of double-blind HRS group.71.4% in the randomized HRS group and 68.2% in 192 cases of 42 cases of un-controled HRS group.It is suggested that HRS could largely elevate the survival rate of the patients with AVH.